Early trial tests new combo against deadly brain cancer spread
NCT ID NCT06724926
Summary
This early-stage study is testing the safety of combining an oral drug called azeliragon with full brain and spine radiation in patients with aggressive cancer that has spread to the lining of the brain and spinal cord. The main goal is to find out if this combination is safe and what side effects it causes. Researchers will also track if the treatment helps slow the cancer's progression in the nervous system and improves survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.